The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC.
 
Tawee Tanvetyanon
No Relationships to Disclose
 
Dung-Tsa Chen
No Relationships to Disclose
 
Jhanelle E. Gray
Honoraria - AstraZeneca; Daiichi Sankyo, Inc; EMD Serono/Merck; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Merck; Merck; OncoCyte; Pfizer; Regeneron; Spectrum ODAC; Triptych Health Partners
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/UCB Japan; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Jazz Pharmaceuticals; Merck; Merck; Pfizer; Regeneron; Spectrum Pharmaceuticals; Triptych Health Partners
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Services (Inst); Lilly (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie; OncoCyte; Spectrum Pharmaceuticals